Predictors and moderators of relapse in children and adolescents with major depressive disorder

Beth D. Kennard, Taryn L. Mayes, Zohra Chahal, Paul A. Nakonezny, Alexandra Moorehead, Graham J. Emslie

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To identify predictors and moderators of relapse during continuation treatment among depressed youth randomly assigned to fluoxetine or placebo. Methods: Potential predictors and moderators of relapse that were identified by a literature review were examined in 102 youth (aged 7-18 years), diagnosed with major depressive disorder as defined by DSM-IV criteria, who were considered responders after 12 weeks of fluoxetine treatment (acute phase). This randomized controlled trial was conducted from June 2000 through October 2005. Each candidate predictor and moderator was evaluated with a multiple logistic regression model to examine the main and interaction effects of 12 weeks of continuation treatment on relapse status (at week 24) while controlling for age, sex, and depression severity. Relapse was defined as a Children's Depression Rating Scale-Revised total score = 40 with worsening of depressive symptoms for at least 2 weeks. Results: Youth with comorbid dysthymia (adjusted odds ratio [OR] = 2.88, P =.03) and low levels of family leadership (adjusted OR = 1.39, P =.006) at baseline are more likely to relapse than their counterparts. Higher levels of depression (OR = 1.21, P =.003) and higher levels of residual sleep disturbance (insomnia) (OR = 6.74, P =.006) and irritability (OR = 7.40, P =.01) at the end of acute treatment (12 weeks) increased the odds of relapse. Higher levels of depressive symptoms at baseline in youth who remained on fluoxetine for continuation treatment were associated with increased odds of relapse (adjusted OR = 1.14, P =.03). Females who remained on fluoxetine for the duration of continuation treatment were almost 9 times more likely to relapse than males (adjusted OR = 8.86, P =.007). Conclusions: This is the first large continuation study for treatment of depression in youth to examine predictors and moderators of relapse. Youth with greater improvement by the end of 3 months of treatment were less likely to relapse than those with continued depressive symptoms. In addition, youth with comorbid dysthymia had 3 times greater risk of relapse than those without. Targeting residual symptoms, particularly sleep disturbance and irritability, earlier in treatment may reduce relapse rates.

Original languageEnglish (US)
Article number15m10330
JournalJournal of Clinical Psychiatry
Volume79
Issue number2
DOIs
StatePublished - Mar 1 2018

Fingerprint

Major Depressive Disorder
Recurrence
Odds Ratio
Depression
Fluoxetine
Therapeutics
Sleep
Logistic Models
Sleep Initiation and Maintenance Disorders
Diagnostic and Statistical Manual of Mental Disorders
Randomized Controlled Trials
Placebos

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Predictors and moderators of relapse in children and adolescents with major depressive disorder. / Kennard, Beth D.; Mayes, Taryn L.; Chahal, Zohra; Nakonezny, Paul A.; Moorehead, Alexandra; Emslie, Graham J.

In: Journal of Clinical Psychiatry, Vol. 79, No. 2, 15m10330, 01.03.2018.

Research output: Contribution to journalArticle

@article{490c7497171f47fdb9be1f7b189c7692,
title = "Predictors and moderators of relapse in children and adolescents with major depressive disorder",
abstract = "Objective: To identify predictors and moderators of relapse during continuation treatment among depressed youth randomly assigned to fluoxetine or placebo. Methods: Potential predictors and moderators of relapse that were identified by a literature review were examined in 102 youth (aged 7-18 years), diagnosed with major depressive disorder as defined by DSM-IV criteria, who were considered responders after 12 weeks of fluoxetine treatment (acute phase). This randomized controlled trial was conducted from June 2000 through October 2005. Each candidate predictor and moderator was evaluated with a multiple logistic regression model to examine the main and interaction effects of 12 weeks of continuation treatment on relapse status (at week 24) while controlling for age, sex, and depression severity. Relapse was defined as a Children's Depression Rating Scale-Revised total score = 40 with worsening of depressive symptoms for at least 2 weeks. Results: Youth with comorbid dysthymia (adjusted odds ratio [OR] = 2.88, P =.03) and low levels of family leadership (adjusted OR = 1.39, P =.006) at baseline are more likely to relapse than their counterparts. Higher levels of depression (OR = 1.21, P =.003) and higher levels of residual sleep disturbance (insomnia) (OR = 6.74, P =.006) and irritability (OR = 7.40, P =.01) at the end of acute treatment (12 weeks) increased the odds of relapse. Higher levels of depressive symptoms at baseline in youth who remained on fluoxetine for continuation treatment were associated with increased odds of relapse (adjusted OR = 1.14, P =.03). Females who remained on fluoxetine for the duration of continuation treatment were almost 9 times more likely to relapse than males (adjusted OR = 8.86, P =.007). Conclusions: This is the first large continuation study for treatment of depression in youth to examine predictors and moderators of relapse. Youth with greater improvement by the end of 3 months of treatment were less likely to relapse than those with continued depressive symptoms. In addition, youth with comorbid dysthymia had 3 times greater risk of relapse than those without. Targeting residual symptoms, particularly sleep disturbance and irritability, earlier in treatment may reduce relapse rates.",
author = "Kennard, {Beth D.} and Mayes, {Taryn L.} and Zohra Chahal and Nakonezny, {Paul A.} and Alexandra Moorehead and Emslie, {Graham J.}",
year = "2018",
month = "3",
day = "1",
doi = "10.4088/JCP.15m10330",
language = "English (US)",
volume = "79",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "2",

}

TY - JOUR

T1 - Predictors and moderators of relapse in children and adolescents with major depressive disorder

AU - Kennard, Beth D.

AU - Mayes, Taryn L.

AU - Chahal, Zohra

AU - Nakonezny, Paul A.

AU - Moorehead, Alexandra

AU - Emslie, Graham J.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objective: To identify predictors and moderators of relapse during continuation treatment among depressed youth randomly assigned to fluoxetine or placebo. Methods: Potential predictors and moderators of relapse that were identified by a literature review were examined in 102 youth (aged 7-18 years), diagnosed with major depressive disorder as defined by DSM-IV criteria, who were considered responders after 12 weeks of fluoxetine treatment (acute phase). This randomized controlled trial was conducted from June 2000 through October 2005. Each candidate predictor and moderator was evaluated with a multiple logistic regression model to examine the main and interaction effects of 12 weeks of continuation treatment on relapse status (at week 24) while controlling for age, sex, and depression severity. Relapse was defined as a Children's Depression Rating Scale-Revised total score = 40 with worsening of depressive symptoms for at least 2 weeks. Results: Youth with comorbid dysthymia (adjusted odds ratio [OR] = 2.88, P =.03) and low levels of family leadership (adjusted OR = 1.39, P =.006) at baseline are more likely to relapse than their counterparts. Higher levels of depression (OR = 1.21, P =.003) and higher levels of residual sleep disturbance (insomnia) (OR = 6.74, P =.006) and irritability (OR = 7.40, P =.01) at the end of acute treatment (12 weeks) increased the odds of relapse. Higher levels of depressive symptoms at baseline in youth who remained on fluoxetine for continuation treatment were associated with increased odds of relapse (adjusted OR = 1.14, P =.03). Females who remained on fluoxetine for the duration of continuation treatment were almost 9 times more likely to relapse than males (adjusted OR = 8.86, P =.007). Conclusions: This is the first large continuation study for treatment of depression in youth to examine predictors and moderators of relapse. Youth with greater improvement by the end of 3 months of treatment were less likely to relapse than those with continued depressive symptoms. In addition, youth with comorbid dysthymia had 3 times greater risk of relapse than those without. Targeting residual symptoms, particularly sleep disturbance and irritability, earlier in treatment may reduce relapse rates.

AB - Objective: To identify predictors and moderators of relapse during continuation treatment among depressed youth randomly assigned to fluoxetine or placebo. Methods: Potential predictors and moderators of relapse that were identified by a literature review were examined in 102 youth (aged 7-18 years), diagnosed with major depressive disorder as defined by DSM-IV criteria, who were considered responders after 12 weeks of fluoxetine treatment (acute phase). This randomized controlled trial was conducted from June 2000 through October 2005. Each candidate predictor and moderator was evaluated with a multiple logistic regression model to examine the main and interaction effects of 12 weeks of continuation treatment on relapse status (at week 24) while controlling for age, sex, and depression severity. Relapse was defined as a Children's Depression Rating Scale-Revised total score = 40 with worsening of depressive symptoms for at least 2 weeks. Results: Youth with comorbid dysthymia (adjusted odds ratio [OR] = 2.88, P =.03) and low levels of family leadership (adjusted OR = 1.39, P =.006) at baseline are more likely to relapse than their counterparts. Higher levels of depression (OR = 1.21, P =.003) and higher levels of residual sleep disturbance (insomnia) (OR = 6.74, P =.006) and irritability (OR = 7.40, P =.01) at the end of acute treatment (12 weeks) increased the odds of relapse. Higher levels of depressive symptoms at baseline in youth who remained on fluoxetine for continuation treatment were associated with increased odds of relapse (adjusted OR = 1.14, P =.03). Females who remained on fluoxetine for the duration of continuation treatment were almost 9 times more likely to relapse than males (adjusted OR = 8.86, P =.007). Conclusions: This is the first large continuation study for treatment of depression in youth to examine predictors and moderators of relapse. Youth with greater improvement by the end of 3 months of treatment were less likely to relapse than those with continued depressive symptoms. In addition, youth with comorbid dysthymia had 3 times greater risk of relapse than those without. Targeting residual symptoms, particularly sleep disturbance and irritability, earlier in treatment may reduce relapse rates.

UR - http://www.scopus.com/inward/record.url?scp=85046895036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046895036&partnerID=8YFLogxK

U2 - 10.4088/JCP.15m10330

DO - 10.4088/JCP.15m10330

M3 - Article

C2 - 29474007

AN - SCOPUS:85046895036

VL - 79

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 2

M1 - 15m10330

ER -